The aim of this study was to evaluate the socioeconomic related dimension of inequalities in malaria prevention interventions. LLIN coverage was low overall, with rich households more likely to own nets. IRS coverage appeared more equitable.
Dihydroartemisinin-piperaquine (DhP) is highly recommended for the treatment of uncomplicated malaria. This study aims to compare the costs, health benefits and cost-effectiveness of DhP and artemether-lumefantrine (AL) alongside “do-nothing” as a baseline comparator in order to consider the appropriateness of DhP as a first-line anti-malarial drug for children in Tanzania.